Breast Medical Oncologist @clevelandclinic Taussig Can Inst. | Interested in experimental therapeutics #bcsm | @hemeoncgators and @MUSC_COM alum. Views = me
Dr. @AzkaAliMD (@ClevelandClinic) shares how CNN-based AI models (e.g., IbRiS) applied to H&E slides predict DFS/OS in ER+ breast cancer; retrospectively validated across U.S. & India cohorts. Outperforms Oncotype in ILC & Black pts. Scalable, low-cost risk tool. #DAVABreast
USP1 regulates replication fork stability. Dr. @AzkaAliMD (@ClevelandClinic) highlights KSQi (RO7623066) as a USP1i that synergizes with Olaparib. Tumor regressions seen in BRCA1+ mBC; PK and biomarker data support continued study. #DAVABreast
Dr. Shreya Sengupta was a gifted clinician, rising health services researcher, and fierce advocate for the most vulnerable. Her work transformed ALD care and advanced equity in hepatology.
Thank you @AASLDtweets for honoring her legacy. Donate: https://t.co/H0ZGTAaJyf
It's been exactly 20 years since my first day of internship
As I reflect on my disproportionate aging since then (gray hairs >>> wisdom), here are my 10 unsolicited recommendations for any colleague embarking on residency
THE "ATTENDING ADVICE YOU DIDN'T ASK FOR" THREAD ...
That's the world's literature on ivermectin in advanced cancer. 8 pts with TNBC getting ICI + ivermectin, 1 response (same rate as ICI alone, in other trials), avg PFS of 2.5 m. So, at present, there is no evidence for meaningful clinical activity of ivermectin in cancer.
Thanks so much to @AzkaAliMD, of @clevelandclinic, for sitting down with us at #SABCS24 to speak about alternative chemo dosing schedules in breast cancer! Check out our site for insights from Dr Ali and more! @SABCSSanAntonio#bcsm#oncology
https://t.co/4sGPaMZOcg